Quote | Options | News | Analyst Ratings

Last: 22.84

Change: ($0.11)

Percent Change: -0.48

Volume: 169,808

Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans. This results in a diversified product pipeline of complex generic, follow-on biologic and novel drugs. The Company?s two most advanced complex generic product candidates target marketed products, which were originally approved by the United States Food and Drug Administration as New Drug Applications. M-Enoxaparin is designed to be a generic version of Lovenox (enoxaparin sodium injection), a low-molecular weight heparin used to prevent and treat deep vein thrombosis. Its second major generic product candidate is M356, a generic version of Copaxone (glatiramer acetate injection), a drug that is indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis.

12:26:00 PM 7/27/2010
Momenta, Idenix lead drug stocks south
Shares of partners Momenta Pharmaceuticals and Novartis AG fall, a day after rival Sanofi-Aventis filed a federal lawsuit to prevent the companies from launching a generic version of Sanofi's blockbuster drug Lovenox.

4:35:00 PM 7/26/2010
Monday's biggest gaining and declining stocks
MarketWatch's daily rundown of major gainers and decliners in the U.S. stock market includes Alico, A123, Cal-Maine, Delta Petroleum, FMC, Office Depot and Onyx Pharma.

10:32:00 AM 7/26/2010
Onyx, Genzyme, Momenta in spotlight
Onyx Pharmaceuticals and Genzyme Corp. help lead drug stocks into positive territory in early activity during a largely bullish morning for the sector on Wall Street.

10:00:00 AM 7/26/2010
Critical Insider Trade News for QLogic, Momenta Pharmaceuticals, Skyworks, T. Rowe Price, E*TRADE Financial, & Biogen Idec; Reported by Insiderslab.com
VANCOUVER, Canada, July 26, 2010 /PRNewswire via COMTEX/ -- Today Insiderslab.com issues new research reports on large insider trades found in the above Blue Chips or Penny Stock companies. Insiders refer to company C-Level Officers (CEOs, CFOs, COOs) and Directors who are involved in making critical corporate decisions. There are thousands of insider filings on the stock markets every day. Insiderslab.com strives to turn this massive raw data into usable information that investors can use to do better research for their investments.

3:33:00 PM 7/23/2010
Sanofi, Genzyme move on M&A rumors, FDA move
Shares of Genzyme Corp. soared while Sanofi-Aventis shares fell Friday amid rumors that Sanofi was in talks to acquire the troubled biotechnology company and on word that U.S. regulators have approved a generic version of one of Sanofi's top-selling drugs.

6:00:00 AM 6/14/2010
aTyr Pharma Appoints Catharine E. Johnson As Senior Vice President of Business Development
SAN DIEGO, June 14, 2010 /PRNewswire via COMTEX/ -- aTyr Pharma, Inc. today announced that Catharine E. Johnson, Ph.D. has recently joined the company as its Senior Vice President of Business Development. Dr. Johnson's extensive biotechnology industry experience will help to advance aTyr Pharma's portfolio of resectin-based therapeutics. Resectins are a novel class of endogenous human proteins derived from aminoacyl tRNA synthetases, and have activities relevant to multiple disease areas, including autoimmunity, inflammation, and blood disorders. The privately held biotech was co-founded by Dr. Xianglei Yang and Dr. Paul Schimmel, a leading aminoacyl tRNA synthetase scientist and serial entrepreneur in the biotech sector.